ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $9.00 target price on the stock.
Separately, Piper Sandler reissued an “overweight” rating and set a $10.00 price objective (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research note on Wednesday, March 13th.
View Our Latest Stock Analysis on ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Price Performance
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last announced its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. Research analysts anticipate that ASLAN Pharmaceuticals will post -2.68 earnings per share for the current year.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Featured Stories
- Five stocks we like better than ASLAN Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What is a Death Cross in Stocks?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.